Friday, February 27, 2015

Biocept, Inc. (BIOC) Utilizing Proprietary Diagnostic Tools to Improve the Lives of Cancer Patients

Biocept is dedicated to improving the outcomes for cancer patients by developing innovative diagnostic solutions. The company’s primary diagnostic tool, known as a liquid biopsy, allows patients and doctors to gather a host of important information from a simple blood test. Using its patented methodology, the company allows for the isolation of rare cells – such as circulating tumor cells, which are a type of seed that can promote additional tumor growth – without the need for a tissue sample.

The company’s liquid biopsy test is intended to assist physicians in understanding the status of a patient’s disease while contributing to the development of current and future therapy plans. Though treatments for metastic cancer, or cancer that is spread from one organ to another organ in a different area of the body, have advanced in recent years, timely diagnosis of the disease remains critical for the patient’s overall odds of survival. According to a report from the American Cancer Society, the chances of surviving metastic cancer are greatly increased if it is diagnosed in its early stages.

While doctors have already used the company’s biomarker technology to successfully assist thousands of patients, Biocept is continuing to study the diagnostic potential of its blood-based tools. The company recently completed a trial that showed the effectiveness of its proprietary technology in determining hormonal status in metastatic breast cancer patients.

“We are encouraged that the results of this study further support the validity of Biocept’s liquid biopsy in the continuous monitoring and treatment of breast cancer,” said Veena Singh, M.D., Senior Vice President and Senior Medical Director of Biocept.

Comments from doctors involved in the recent study indicated that the company’s diagnostic tool could have significant implications on the treatment of cancer patients for whom tissue samples are not feasible.

Biocept currently offers CLIA validated tests for breast, lung and gastric cancers, and the company plans to conduct additional studies for colorectal, prostate and other solid tumors using its proprietary platforms in the future.

For more information, visit www.biocept.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html